The experimental model FFHR showed hypertension, dyslipidemia, insulin resistance, vascular and cardiac remodeling, inflammation demonstrated by increased hsCRP and vascular inflammation by increased the NF-κB expression, VCAM-1, and proatherogenic cytokines. This evidence concerns the gene VCAM1 and metabolic syndrome.